Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
1. JNJ's Q2 earnings expected at $2.68, down from $2.82 last year. 2. Projected revenue for JNJ is $22.86 billion, slightly up from $22.45 billion. 3. FDA application submitted for CAPLYTA to prevent schizophrenia relapse. 4. Morgan Stanley raised JNJ's price target to $171 while others remain cautious. 5. Recent stock performance shows a slight gain of 0.9% to $157.69.